The Cooper Companies, Inc. (NASDAQ:COO) Shares Acquired by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP lifted its position in The Cooper Companies, Inc. (NASDAQ:COO) by 37.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 14,412 shares of the medical device company’s stock after buying an additional 3,954 shares during the quarter. Brevan Howard Capital Management LP’s holdings in Cooper Companies were worth $1,325,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Byrne Asset Management LLC purchased a new stake in Cooper Companies during the 4th quarter worth about $33,000. OFI Invest Asset Management purchased a new stake in shares of Cooper Companies during the fourth quarter worth approximately $34,000. New Age Alpha Advisors LLC acquired a new stake in Cooper Companies in the fourth quarter valued at approximately $38,000. Covestor Ltd lifted its stake in Cooper Companies by 35.5% in the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock worth $42,000 after acquiring an additional 120 shares during the last quarter. Finally, West Financial Advisors LLC acquired a new position in Cooper Companies during the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $81.25 on Thursday. The firm has a market capitalization of $16.25 billion, a price-to-earnings ratio of 41.67, a price-to-earnings-growth ratio of 2.25 and a beta of 1.08. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The business’s 50 day simple moving average is $80.88 and its 200-day simple moving average is $91.35. The Cooper Companies, Inc. has a 12 month low of $69.81 and a 12 month high of $112.38.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million for the quarter, compared to analyst estimates of $981.25 million. As a group, equities analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

COO has been the subject of a number of recent research reports. Robert W. Baird decreased their price objective on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Friday, March 7th. Piper Sandler restated an “overweight” rating and set a $115.00 price objective (down previously from $120.00) on shares of Cooper Companies in a research report on Friday, March 7th. JPMorgan Chase & Co. lowered their target price on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Finally, Stifel Nicolaus reduced their price objective on shares of Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.25.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.